Genomic Prediction

Genomic Prediction Inc. (GP) provides advanced genomic tests that improve IVF health outcomes through preimplantation genetic testing (PGT). Founded in 2017, GP offers a full suite of embryo genetic tests via its LifeView platform including PGT-A (aneuploidy screening), PGT-A+ (parental origin of chromosomal abnormalities), PGT-M (monogenic diseases), PGT-SR (structural rearrangements), and M2 (miscarriage risk). Its flagship Embryo Health Score Test evaluates polygenic disease risk for conditions such as diabetes, cardiovascular disease, and cancer, allowing clinicians and patients to compare embryos by disease risk before transfer. GP's methodology combines dense genome-wide genotyping with machine learning to deliver higher pregnancy rates and lower miscarriage rates than conventional testing.